Ashley McEvoy named Insulet CEO

McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.

By Elise Reuter • April 28, 2025

Trump’s tariff effect has dominated medtech earnings calls

While J&J, Abbott and Boston Scientific have all said the White House’s tariff policies will cost them hundreds of millions of dollars, yearly forecasts have remained in place — or even increased.

By Ricky Zipp • April 28, 2025

Medtronic submits Hugo soft tissue robot for FDA approval

William Blair analyst Brandon Vazquez said 2025 could be the first year market leader Intuitive Surgical will face meaningful U.S. competition.

By Susan Kelly • April 28, 2025

Bausch + Lomb will resume intraocular lens sales weeks after recall

An analysis of the timing of adverse event reports has convinced the company that raw material delivered by a vendor was the source of the problem.

By Nick Paul Taylor • April 28, 2025

Boston Scientific CFO Dan Brennan to retire after nearly 30 years with the company

Jon Monson, currently Boston Scientific's senior vice president for investor relations, will replace Brennan beginning June 30.

By Nick Paul Taylor • April 25, 2025

Michael Greiner leaves Avanos over offer under new CEO

Avanos did not offer Greiner a position comparable to the one he held before becoming interim CEO last year.

By Nick Paul Taylor • April 25, 2025

Medtronic seeks FDA nod for insulin pump, furthering Abbott collab

Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.

By Elise Reuter • April 24, 2025

Device developers advance AI plans despite Trump uncertainty

Trump administration policies have raised questions about how the FDA will regulate AI in medical devices. AdvaMed board members think the agency should keep its leading role.

By Elise Reuter • April 24, 2025

Edwards shrugs off tariffs, backs 2025 profit forecast

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity constraints that have dogged its core business.

By Susan Kelly • Updated April 30, 2025

Field Medical raises $40M for PFA in ventricular tachycardia

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart rhythm disorder.

By Susan Kelly • April 23, 2025

Intuitive lowers profit margin forecast due to tariff pressure

CFO Jamie Samath cautioned that the trade environment, financial pressures on hospitals and macroeconomic risks could extend timelines for robot purchases.

By Susan Kelly • April 23, 2025

Who are the United States’ top trading partners?

Explore how over 200 countries’ imports, exports and trade balances with the U.S. last year stack up in this sortable chart.

By Edwin Lopez • April 23, 2025

FDA issues early alert for BD catheters due to leaks

BD recalled certain intravascular catheters tied to reports of 10 serious injuries after finding an increase in cracks from “material fatigue.”

By Susan Kelly • April 21, 2025

Precision Neuroscience receives FDA clearance for brain implant

The electrode array, which can be implanted for 30 days to map brain activity, is a component of Precision Neuroscience’s planned brain-computer interface system.

By Elise Reuter • April 21, 2025

Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps

The updated device allows users to pair the sensor with Medtronic’s insulin pumps, and is expected to grow the company’s diabetes business.

By Elise Reuter • April 21, 2025

Dr. Oz sworn in as CMS administrator

During a ceremony at the Oval Office, Mehmet Oz said he would focus on reducing chronic disease, “modernizing” Medicare and Medicaid, and targeting fraud, waste and abuse in government insurance offerings.

By Emily Olsen • April 21, 2025

Intuitive, Boston Scientific and Edwards next up in medtech earnings

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and competitive dynamics in key markets.

By Nick Paul Taylor • April 21, 2025

Ceribell wins FDA nod for algorithm to detect pediatric seizures

The clearance adds another feature for Ceribell to leverage as it tries to persuade hospitals to switch from conventional EEG systems.

By Nick Paul Taylor • April 21, 2025

Illinois, Minnesota join FTC challenge against $627M Surmodics buyout

The Illinois attorney general said the deal represents a “troubling trend of wealthy investors attempting to limit competition and innovation.”

By Nick Paul Taylor • April 18, 2025

FDA cuts outlined in draft HHS budget

The draft budget would slash FDA’s budget authority, if approved by Congress.

By Elise Reuter • April 18, 2025

Budget draft outlines Trump’s plan to slash federal health programs

An OMB document proposes to cut the HHS budget by roughly one-third as well as eliminate several divisions and programs.

By Sydney Halleman • April 17, 2025

DaVita hit by ransomware attack

The kidney dialysis firm doesn’t have an estimate for how long disruption from the attack will last, though DaVita stressed it’s continuing to provide patient care.

By Emily Olsen • April 17, 2025

Abbott expects a ‘few hundred million’ in tariff costs in 2025

CEO Robert Ford told investors the company had considered raising its earnings forecast for 2025, but decided to maintain it in light of the new tariffs.

By Elise Reuter • April 16, 2025

US launches probe into semiconductor imports

The Section 232 investigation comes ahead of anticipated tariffs on the industry.

By Philip Neuffer • April 15, 2025

J&J expects tariff charge of $400M this year

CFO Joe Wolk, who revealed the figure Tuesday morning on CNBC, told investors the charge was primarily in the healthcare giant’s medtech business.

By Ricky Zipp • April 15, 2025